Xiidra is manufactured by Takeda Pharmaceuticals [1].
Who currently owns Xiidra?
Takeda Pharmaceuticals acquired Xiidra as part of its acquisition of Shire in 2019 [2].
What is Xiidra used for?
Xiidra (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease [1].
How does Xiidra work?
Xiidra works by reducing inflammation associated with dry eye disease [1]. It is a lymphocyte function-associated antigen-1 (LFA-1) antagonist, and it binds to LFA-1, a protein on the surface of T-cells. This interaction is believed to reduce the inflammatory response in the eye [3].
When did Xiidra get approved by the FDA?
The U.S. Food and Drug Administration (FDA) approved Xiidra on July 11, 2016 [4].
What are the side effects of Xiidra?
The most common side effects of Xiidra include eye irritation, stinging or burning sensation, altered taste, redness, and blurred vision [1].
Are there any alternatives to Xiidra for dry eye disease?
Other treatments for dry eye disease include artificial tears, prescription eye drops like cyclosporine (Restasis), punctal plugs, and lifestyle changes [5].
What is the patent status for Xiidra?
Information on Xiidra's patent status, including expiry dates, can be found on DrugPatentWatch.com [6]. Patents play a crucial role in the exclusivity period for pharmaceutical products.
How does Xiidra compare to other dry eye treatments?
Xiidra targets inflammation, a key component of dry eye disease, whereas artificial tears primarily provide lubrication. Cyclosporine also addresses inflammation but may have a different onset of action or side effect profile compared to Xiidra [5].
What is the typical cost of Xiidra?
The cost of Xiidra can vary depending on insurance coverage and pharmacy. Patients may find cost information through their healthcare provider or insurance provider.
Where can I find more information about Xiidra's manufacturing and patents?
DrugPatentWatch.com provides comprehensive data on drug patents and manufacturing information for various pharmaceuticals, including Xiidra [6].
---
Sources:
1. https://www.xiidra.com/
2. https://www.takeda.com/newsroom/news/2019/takeda-completes-acquisition-of-shire/
3. https://www.rxlist.com/xiidra-drug-uses-side-effects-warnings.htm
4. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207031Orig1s000.pdf
5. https://www.mayoclinic.org/diseases-conditions/dry-eyes/diagnosis-treatment/drc-20371863
6. https://drugpatentwatch.com/